glp-1 receptor agonist after roux-en-y gastric bypass Greater early postprandial increase than one-anastomosis bypass, with unchanged secretin: a randomized controlled trial Frontiers | Mechanisms of action

It acts as a bispecific molecule, combining GLP-1 receptor agonism with GIP receptor antagonism to promote weight loss

Explore the pros and cons of GLP-1 medications for managing type 2 diabetes and weight loss.

The products are being advertised as more affordable alternatives to blockbuster weight-loss drugs

Thirteen trials involving 5,807 participants were identified

Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant

Here, we test whether GLP-1RAs alter alcohols peripheral pharmacokinetics as a potential mechanism of action for their alcohol intake suppressive effects